Peripheral Vasodilation in Obese Humans

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The growing population of obese adults is predicted to create a large public health burden in the next few decades. This study examines function of small blood vessels providing blood flow to skeletal muscles, to test if younger obese individuals (≤40 years old, BMI >30) are already displaying reductions in blood vessel function. This study will test if the signals blood vessels use to increase blood flow are changing in these same subjects. Findings from this study may help create treatments to delay or prevent some of the negative effects of obesity on vascular health.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Wisconsin, Madison
• Collaborator: National Heart, Lung, and Blood Institute (NHLBI)

Criteria

Inclusion Criteria:

• Age: ≥18 - ≤ 40 years of age

• Blood pressure systolic ≤125 and diastolic ≤85 mmHg (Lean control) and <140 and diastolic <90 mmHg (Obese subjects)

• BMI <25 kg/m2 (Lean control) and ≥30 kg/m2 (Obese subjects)

• Fasting blood glucose <100 mg/dL

• Fasting LDL <130 mg/dL

• Fasting blood triglycerides <150 mg/dL

• Females: Premenopausal with a regular menstrual cycle. Negative pregnancy test. Note:

Must be studied in the early follicular phase (day 1-5) of their menstrual cycle or the low hormone phase of oral contraceptive use.

Exclusion Criteria:

• Specific to obese subjects only (to exclude obese subjects with metabolic syndrome):

a. If Systolic BP 130 ≤ BP < 140 mmHg or Diastolic BP 85 ≤ BP < 90 mmHg i. HDL < 40 mg/dL for men ii. HDL < 50 mg/dL for women

• Increased risk of bleeding

• Sensitivity to lidocaine

• Procoagulant or other clotting disorders

• Taking cardiovascular medications (anti-hypertensives, statins, platelet inhibitors, etc.) or metabolic medications (insulin-sensitizing)

• Regularly (≥5 days/week) take acetylsalicylic acid and/or non-steroidal anti-inflammatory drugs (NSAIDs)

• Self-reported current diagnosis of exhibiting obstructive sleep apnea

• Self-reported current or past diagnosis of diabetes

• Self-reported history of peripheral vascular disease

• Self-reported history of hepatic disease

• Self-reported history of renal disease

• Self-reported history of hematologic disease

• Self-reported history of stroke

• Current use of tobacco (i.e. smoke, smokeless, and vapor). Prior tobacco use with >1 year abstaining is allowed.

• Participation in vigorous aerobic exercise >90 minutes per week

• Arterial structures in the arm that are not conducive to study in the laboratory setting

• Females: Self-reported pregnancy and/or breastfeeding, diagnosed with polycystic ovarian syndrome, or without regular menses. Urine pregnancy test will be performed on study day to ensure subject is not pregnant on study day.

• An abnormality or contraindication to study participation which is not covered in the eligibility criteria.